Servatrix

Servatrix Biomed S.L. is a biotechnology firm that emerged as a spin-off from the Autonomous University of Madrid (UAM) and the Spanish National Research Council (CSIC) in November 2022. The company's creation is the culmination of over 15 years of dedicated research into the NRF2 protein, a key regulator of cellular defense mechanisms. This extensive research background was primarily driven by co-founder and Chief Scientific Officer, Dr. Antonio Cuadrado, a Professor of Biochemistry at UAM and a world-renowned expert on NRF2 with over 200 scientific publications. He is joined by co-founder Jorge Cuadrado, who serves as the company's CEO.

The firm focuses on developing treatments for chronic diseases, with a primary emphasis on Non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease affecting over a quarter of the global population. The market for NASH treatments is substantial, given the current lack of widely approved and effective drug therapies. Servatrix's core business involves the research, development, and eventual commercialization of pharmacological products. Its business model is centered on advancing its patented pipeline of NRF2 activators through preclinical and clinical trials, with the ultimate goal of bringing a new drug to market.

Servatrix is developing a portfolio of new pharmacological compounds designed to mildly activate the NRF2 transcription factor. This protein protects against oxidative, inflammatory, and metabolic stress—all critical factors in the progression of NASH. Unlike other strategies that can cause excessive activation, Servatrix's approach allows for a more moderate and balanced therapeutic effect, minimizing potential risks. The company's lead compound has already demonstrated in preclinical models its ability to block the buildup of liver fat and stop the progression of fibrosis, without adverse effects. This patent-protected pipeline offers a distinct method for treating chronic liver disease.

Keywords: Servatrix Biomed, NRF2 activators, non-alcoholic steatohepatitis, NASH treatment, chronic liver disease, biotechnology, pharmaceutical development, Autonomous University of Madrid spin-off, Antonio Cuadrado, Jorge Cuadrado, preclinical trials, drug development, metabolic stress, oxidative stress, fibrosis, fatty liver disease, MASLD, deeptech, pharmacological regulation, molecular biology